PubMed HealthSearch

Biomedical subjects

W Siegmund

Publications and source records attributed to W Siegmund.

At least 19 recordsLinked to original sources

Pharmacokinetic interactions between isoniazid and theophylline in rats.

Pharmacokinetic interactions between isoniazid and theophylline were studied in male Wistar rats, 206 +/- 17 g. Concomitant oral administration of 2 x 5 mg kg-1 isoniazid accelerated slightly the disposition of theophylline (10 mg kg-1, i.v.) whereas 2 x 25 mg kg-1 isoniazid slowed it marginally. The differences in distribution volume, systemic clearance and area under the concentration-time curve (AUC) between the high and the low dose, however, were statistically significant. One week pretreatment with 10 mg kg-1 isoniazid tended towards inhibition (significant decrease of systemic clearance, increase of AUC) and 50 mg kg-1 to acceleration (decrease of half-life, mean residence time and AUC, increase of systemic clearance) of theophylline disposition. After oral pretreatment with 20 mg kg-1 theophylline, neither the kinetics of free isoniazid (50 mg kg-1, i.v.) and the amount acetylated nor the acetylation indices differed from the controls. There was no evidence that concomitant or subacute administration of different doses of isoniazid affects major metabolic pathways of theophylline or that prolonged theophylline treatment interacts with the N-acetylation capacity.

Animals

Effects of isoniazid on hepatic drug oxidation and N-acetylation capacities in rats.

In vitro and in vivo activity of hepatic monooxygenase as well as in vivo N-acetylation capacity were assessed in male Wistar rats after oral pretreatment with 10 and 50 mg/kg isoniazid for 7 d. Both doses of isoniazid showed no statistical difference in protein contents, total cytochrome P-450 and the activities of aminopyrine N-demethylase as well as ethoxyresorufin-O-deethylase in the 9000 x g liver homogenate suspension compared to the saline pretreated group. Body and relative liver weights remained also unchanged. In vivo isoniazid pretreatment with either dose hardly changed the kinetic profiles and parameters of phenazone and sulfadimidine (free + total). The results suggest that drug metabolizing pathways that can be evaluated by the metabolism of the model substances employed here may not be modified by prolonged isoniazid treatment.

Acetylation

Bioavailability of metronidazole formulations (Vagimid).

The bioavailability of metronidazole (0.5 g) from Vagimid tablets and dragées were compared with tablets of a reference formulation in 12 male healthy volunteers (age 20-32 years, body weight 61-77 kg). Metronidazole and its two main oxidized metabolites in serum were determined quantitatively with an hplc method. Metronidazole from Vagimid tablets was absorbed more rapidly than from the reference but at the same extent of absorption. The pharmacokinetic profile of Vagimid dragées was similar to the behaviour of the reference but AUC of dragées was slightly but significantly lower. All elimination parameters of metronidazole as well as the formation of the two metabolites were not different after administration of the oral formulations.

Adult

Drug oxidation and N-acetylation in rats pretreated with subtoxic doses of streptolysin O.

SLO in sublytic doses (100 HU/kg body wt) depressed the hepatic microsomal cytochrome P450 and aminopyrine-N-demethylase but increased significantly the cytosolic N-acetyltransferase after acute and subacute (5 days) pretreatment of male Wistar rats. Aniline hydroxylase was reduced after acute and unchanged after subacute pretreatment. The effects of SLO on the oxidative enzymes and drug N-acetylation might have been caused by the membranal and immunological properties of the toxin.

Aniline Hydroxylase

N-acetylation and debrisoquine hydroxylation polymorphisms in patients with Gilbert's syndrome.

1. N-acetylation and debrisoquine hydroxylation phenotypes were determined in 54 patients with Gilbert's syndrome and in 247 (sulphamethazine) and 76 (debrisoquine) non-related healthy volunteers. 2. Forty (74.1%) of the patients and 135 (54.7%) of the healthy volunteers were slow acetylators (chi 2 = 6.87). In the patients, the cumulative urinary excretion of sulphamethazine up to 6 h (Ae(0,6)) was significantly lower. No differences in the frequency of debrisoquine poor metabolizers were observed: Gilbert's syndrome 5/54 (9.3%), healthy volunteers 5/76 (6.6%). The metabolic ratios were similar in both groups as well as the urinary recoveries of debrisoquine and its 4-hydroxy metabolite. 3. Gilbert's syndrome seems to be related in some way to N-acetylation but not to the debrisoquine hydroxylation polymorphism.

Acetylation

N-acetylation and oxidative capacity in aged volunteers determined with sulfamethazine and antipyrine.

The elimination of antipyrine (AP 15 mg/kg) and sulfamethazine (SM 500 mg) was measured in healthy volunteers of rapid and slow acetylator phenotype. Nineteen males were 20-32 years of age, 11 males and 6 females between 62-86 years of age. Apparent volume of distribution of AP was reduced in advanced age independent of the acetylator status of the individuals. Total body clearance was significantly lower and half-time and mean residence time were higher only in slow but not in rapid acetylators. In the elderly of both phenotypes, the acetylation ratios of SM were significantly enhanced. Renal and metabolic clearance were decreased and AUC-values of SM and its acetylated metabolite were increased in slow but unchanged in rapid acetylators. Physiological peculiarities of distribution and renal excretion of SM and its acetylated metabolite in advanced age may have caused the contradictory results.

Acetylation

Pharmacokinetics of almitrine in healthy volunteers and patients with essential hypertension.

Pharmacokinetic studies with the arterial chemoreceptor stimulant almitrine (100 mg per os) were performed in 12 healthy volunteers and 8 patients with essential hypertension stage I in order to evaluate the suitability of the drug for physiological tests. The parent compound was determined gas-chromatographically. Almitrine was absorbed with maximal serum levels after 1.8 +/- 0.4 h in healthy volunteers and 1.5 +/- 0.3 h in patients. The elimination proceeded biexponentially with terminal half-lives from 14.6 to 43.4 h in volunteers and 12.5-45.0 h in patients. Further characteristics were large distribution volumes (16.1 +/- 4.5 ml/g in healthy volunteers, 13.9 +/- 4.7 ml/g in patients) and large interindividual variations of all pharmacokinetic parameters by a factor of 2 to 6. Significant differences between healthy individuals and patients were not observed. The drug was well tolerated. The pharmacokinetic properties of almitrine should be included into its evaluation as a test compound.

Administration, Oral

N-acetylation and debrisoquine type oxidation polymorphism in Caucasians--with reference to age and sex.

Phenotypes of the N-acetylation and debrisoquine type oxidation polymorphism were determined with sulfamethazine and debrisoquine in 145 healthy volunteers (31-80 years, 64 males, 81 females) of a North-East German area. Seventeen (11.7%) were poor metabolizers of debrisoquine and 81 (55.9%) slow acetylators of sulfamethazine. No significant correlations between the frequencies of oxidation and acetylation phenotypes, age, and sex were found. Only a tendency of rapid acetylators to accumulate among individuals above 60 years was noticed. Parameters of phenotyping were not influenced by sex. With age, metabolic ratios of N-acetylation but not of oxidation phenotyping increased. The urinary excretion (0-8 hours) of debrisoquine, sulfamethazine and their metabolites was strikingly reduced in the elderly. Misclassifications of acetylation phenotyping cannot be excluded because of the age dependent kinetics of the test drug.

Acetylation

Oxidation phenotyping with debrisoquine in Germany (East).

An hplc method is described which determines debrisoquine and its metabolite, 4-hydroxydebrisoquine, quantitatively after conversion of the guanidine moieties into the corresponding pyrimidines. Sensitivity, precision, and accuracy have been sufficient enough for the reliable hydroxylation phenotyping of 145 non-related healthy volunteers (64 males, 81 females, 31-80 years). 17 (11%) were poor metabolizers of debrisoquine (gene frequency: 34.2%).

Adult

[The acetylator phenotype in patients with urinary bladder cancer].

In 53 patients suffering from bladder cancer the acelylization phenotype was examined. The frequency of slow acetylizers (70%) was significantly higher than in the control group. The more frequently occurrence of slow acetylizers in the group with professional pollutant exposition is an important reference to a higher bladder cancer morbidity in the case of carcinogen contact. A screening of the acetylization phenotype in professions with carcinogen contact may be important in the prophylaxis of bladder cancer.

Acetylation

Kinetics of antipyrine and sulfamethazine in patients recovered from dihydralazine-hepatitis.

Pharmacokinetic studies with sulfamethazine (500 mg) and antipyrine (15 mg/kg) were performed in 27 hypertonic patients (16 females, 11 males, 37-78 years) who had recovered from a dihydralazine-induced hepatitis, and 21 patients with essential hypertension (13 females, 8 males, 18-74 years) treated with antihypertonics excluding dihydralazine. 20 patients of the hepatitis group (74%) and 12 patients of the control group (57%) were slow acetylators. With regard to the pharmacokinetic parameters no differences were found in both slow and rapid acetylators between the sulfamethazine group and the antipyrine group.

Acetylation